ALPHARETTA, Ga., June 08, 2022 (World NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the shipping of therapies to the back again of the eye by way of the suprachoroidal room (SCS®), introduced nowadays that Thomas A. Ciulla, M.D., MBA, Chief Health care Officer and Main Enhancement Officer, will take part in a Fireside Chat at the JMP Securities Everyday living Sciences Meeting on Wednesday, June 15, 2022, at 9:30 a.m. Jap Time, in New York, NY.
A link to the dwell and archived webcast could be accessed on the Clearside internet site less than the Investors section: Functions and Shows. An archive of the webcast will be obtainable for a few months.
About Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical business revolutionizing the supply of therapies to the back again of the eye by way of the suprachoroidal house (SCS®). Clearside’s SCS injection system, utilizing the Company’s proprietary SCS Microinjector®, permits an in-office environment, repeatable, non-surgical process for the specific and compartmentalized supply of a large range of therapies to the macula, retina or choroid to possibly protect and strengthen vision in clients with sight-threatening eye ailments. Clearside is building its possess pipeline of small molecule solution candidates for administration through its SCS Microinjector and strategically associates its SCS injection platform with organizations employing other ophthalmic therapeutic innovations. Clearside’s to start with product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, is commercially accessible in the U.S. For additional info, remember to take a look at www.clearsidebio.com.
Trader and Media Contacts:
Supply: Clearside Biomedical, Inc.